Compare SCYX & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | ZTEK |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | Canada |
| Employees | 29 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.4M | 68.8M |
| IPO Year | 2014 | 2022 |
| Metric | SCYX | ZTEK |
|---|---|---|
| Price | $0.71 | $0.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 338.4K | 172.9K |
| Earning Date | 05-06-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $608.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.40 |
| 52 Week High | $1.29 | $1.62 |
| Indicator | SCYX | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 53.96 |
| Support Level | $0.59 | $0.69 |
| Resistance Level | $0.70 | $0.82 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 16.89 | 43.56 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.